UK IVD Market Recovery
The BIVDA Market Audit (MA) results for calendar year 2024 have been published and distributed to participating companies.
The total IVD market recovered by about 6% after a drop due to the loss of Covid testing and the slow return to full elective activity, and this was derived from all disciplines except infectious diseases and genetic testing, with strongest growth in Haematology/Haemostasis.
Companies participating in the BIVDA Market Audit have received detailed reports by test type showing changes in volume, share and ranking since 2023.
Once again the UK market, although fifth largest, lags way behind other major markets in expenditure on IVDs per capita, at approximately two-thirds of those in Germany, Belgium, Spain and France, and at 21st place behind the Czech Republic and Estonia.
The European figures referred to above date from 2021 data. Publication of the European IVD Market Report has been suspended for three years. A report for 2024 is expected soon.
For information on how to join the MA, help with report generation or interpretation or other help or information contact John Bagshaw here.
